Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
On February 8, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Camargo Pharmaceutical Services. This collaboration aims to prepare and submit an Investigational New Drug (IND) application for their topical product, HT-001, to the U.S. FDA. The IND is anticipated to receive feedback by February 22, 2021, as Hoth conducts GLP toxicology studies. HT-001 targets skin disorders related to epidermal growth factor receptor inhibitors. The company aims to expedite the NDA submission process through a 505(b)(2) development pathway.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) updated shareholders on its therapeutic pipeline targeting dermatological conditions, COVID-19, and supportive care. Key developments include the BioLexa platform set to begin Phase 1b trials in Q1 2021, positive preclinical results for HT-003 targeting acne, and a Pre-IND meeting with the FDA for HT-001 scheduled for February 22, 2021. CEO Robb Knie emphasized the company’s strengthened balance sheet and optimistic outlook for 2021 as a pivotal growth year, aiming to drive shareholder value through continued advancements in its diverse portfolio.
On January 28, 2021, Hoth Therapeutics, Inc. (HOTH) announced an extension of its research collaboration with Weill Cornell Medicine for HT-003, a novel treatment for acne. This one-year extension follows positive initial results from prior studies indicating HT-003's therapeutic effects on acne-related signaling pathways. The collaboration aims to further investigate HT-003's mechanism and safety in murine models. Dr. Jonathan Zippin will lead the research, underscoring the commitment to developing effective therapies for dermatological conditions.
Hoth Therapeutics (NASDAQ: HOTH) announced the appointment of Dr. Mario Lacouture to its Scientific Advisory Board on January 27, 2021. Dr. Lacouture, a leader in treating skin toxicities from cancer therapies, will oversee the development of HT-001, a topical treatment aimed at managing skin disorders related to epidermal growth factor receptor inhibitor therapy. CEO Robb Knie expressed optimism about leveraging Dr. Lacouture's expertise to advance the clinical program for HT-001, enhancing Hoth's potential therapeutic offerings.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising in vitro findings for HT-003, a potential acne treatment. The research shows that HT-003 significantly inhibits the TLR2 pathway, crucial for acne pathophysiology, and reduces the expression of inflammatory markers in human skin cells. Lead researcher Dr. Jonathan Zippin highlights the drug's potential to benefit patients with various inflammatory skin conditions. Hoth continues to explore HT-003's therapeutic mechanisms through further in vitro studies and animal trials.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that the FDA granted a Pre-IND meeting regarding HT-001, a topical treatment for rash and skin disorders in cancer patients. The meeting, requested on December 22, 2020, will provide FDA feedback on the drug development program, clinical trial designs, and necessary requirements. Feedback is expected by February 22, 2021. CEO Robb Knie expressed hope that the feedback will help expedite HT-001's transition to clinical trials, emphasizing the importance of these developments for the company's future.
On January 11, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Charles River Laboratories to conduct preclinical studies for HT-001, a topical treatment aimed at alleviating rash and skin disorders from EGFR inhibitor cancer therapies. Six preclinical studies are planned, beginning with bioanalytical method development in Q1 2021. The studies aim to fulfill FDA requirements for clinical trial initiation. Hoth's CEO emphasized the collaboration's importance in addressing significant unmet needs in dermatological care.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a definitive securities purchase agreement for a private placement to institutional investors, expected to generate approximately $5.0 million in gross proceeds. Investors will acquire 2,475,248 shares of Common Stock at $2.02, along with warrants for an additional 1,237,624 shares at an exercise price of $2.25. The placement, facilitated by The Benchmark Company, LLC, is set to close on January 7, 2021, subject to customary conditions. The securities, not registered under the Securities Act, may not be resold in the U.S. without appropriate registration.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command for a new antibacterial drug, HT-006, targeting serious lung infections like hospital-acquired pneumonia. The drug aims to combat multi-drug resistant bacteria and will benefit from streamlined development through the FDA's program for unmet medical needs. Preclinical studies are set to commence in Q1 2021, leveraging U.S. Army expertise and resources during development.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has signed a production agreement with Tergus Pharma for GLP and GMP materials related to its cancer treatment drug, HT-001. This follows their request for a Pre-Investigational New Drug meeting with the FDA regarding HT-001, which targets skin disorders associated with EGFR inhibitor therapy. Hoth aims to alleviate dose-limiting skin toxicities, thus enhancing patient outcomes in cancer treatments. CEO Robb Knie expressed optimism for the drug's development and its potential to benefit patients.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
